Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064673 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
A Phase 3 study of Prostate Cancer, sponsored by yair lotan.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 608
- Enrollment target
- 1
- Study location
NCT02064673 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by yair lotan. The registered enrollment target is 608 participants, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02064673, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by yair lotan.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 608 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Curcumin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2014-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064673
The ClinicalTrials.gov registry entry for NCT02064673 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The listed sponsor is yair lotan, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02064673 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02064673 about?
NCT02064673 is a clinical study titled "Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy". This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
What is the current status of trial NCT02064673?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 608 participants. The study started on 2014-05. Estimated completion is 2028-12.
What conditions does trial NCT02064673 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02064673?
The interventions under investigation include: placebo (DRUG), Curcumin (DRUG).
Who is sponsoring clinical trial NCT02064673?
This trial is sponsored by yair lotan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02064673 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.